EUVIMEDDescobrir EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Beyond the Active Site: First‐In‐Class Leishmania Infantum Trypanothione Reductase Dimerization Disruptors as Antileishmanial Leads

María-José Camarasa iD, Miguel Maldonado iD, Alvaro de la Cruz-Potenciano iD, Sonia de Castro iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70513 ↗

At a glance

Übersichtsarbeit in ChemMedChem, 2026. Written by María-José Camarasa and 3 co-authors. Institution: Instituto de Química Médica y Biomedicina (IQMB-CSIC), Madrid, Spain. Major MEDLINE topics: NADH, NADPH Oxidoreductases, Leishmania infantum, Antiprotozoal Agents, Enzyme Inhibitors. 89 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Spanish MINECO, MICINN, and MICIU, Comunidad de Madrid, CSIC.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Leishmania infantum trypanothione reductase (Li‐TryR) is an essential enzyme for parasite redox homeostasis and a validated target for antileishmanial therapy. Classical inhibitors acting at the active site have shown limited success due to poor selectivity, suboptimal pharmacological properties, and lack of in‐cell efficacy. This work presents a comprehensive strategy to develop first‐in‐class Li‐TryR dimerization disruptors, targeting the protein–protein interface required for enzymatic activity. Through molecular modeling, mutagenesis, and structural analysis, a key α‐helical hotspot (around residue E436) was identified as a druggable region. Interface‐derived peptides, helix‐stabilized stapled analogs, α/β‐foldamers, and cell‐penetrating conjugates demonstrated that dimer disruption effectively inhibits LiTryR and can translate into antiparasitic activity. Building on these insights, several families of small‐molecule proteomimetics, including imidazole‐phenyl‐thiazoles, triazole analogs, and triazolium salts, were developed, achieving low‐micromolar to submicromolar inhibition and significant activity in parasite cultures and intracellular models. Overall, this work establishes dimer‐interface targeting as a novel therapeutic paradigm for leishmaniasis and provides multiple optimized chemical scaffolds for future drug development.

Subjects

MeSH terms (MEDLINE)

NADH, NADPH OxidoreductasesLeishmania infantumAntiprotozoal AgentsEnzyme InhibitorsStructure-Activity RelationshipCatalytic DomainMolecular StructureProtein MultimerizationDose-Response Relationship, DrugModels, MolecularTriazolesParasitic Sensitivity TestsDimerization

Author keywords

allosteric dimer destabilizationantileishmanial leadshelix‐mimeticspeptide and proteomimetic inhibitorstrypanothione reductase dimer disruption

Substances

trypanothione reductaseNADH, NADPH OxidoreductasesAntiprotozoal AgentsEnzyme InhibitorsTriazoles

Authors and institutions

  • Instituto de Química Médica y Biomedicina (IQMB-CSIC), Madrid, Spain.

ORCID profiles: María-José Camarasa, Miguel Maldonado, Alvaro de la Cruz-Potenciano, Sonia de Castro

Funding

  • Spanish MINECO, MICINN, and MICIU
  • Comunidad de Madrid
  • CSIC

Cite

APA

Camarasa, M. J., Maldonado, M., de la Cruz-Potenciano, A., & de Castro, S. (2026). Beyond the Active Site: First‐In‐Class Leishmania Infantum Trypanothione Reductase Dimerization Disruptors as Antileishmanial Leads. ChemMedChem. https://doi.org/10.1002/cmdc.70513

Vancouver

Camarasa MJ, Maldonado M, de la Cruz-Potenciano A, de Castro S. Beyond the Active Site: First‐In‐Class Leishmania Infantum Trypanothione Reductase Dimerization Disruptors as Antileishmanial Leads. ChemMedChem. 2026. doi:10.1002/cmdc.70513

BibTeX
@article{Camarasa2026,
  author = {Camarasa, María-José and Maldonado, Miguel and de la Cruz-Potenciano, Alvaro and de Castro, Sonia},
  title = {Beyond the Active Site: First‐In‐Class Leishmania Infantum Trypanothione Reductase Dimerization Disruptors as Antileishmanial Leads},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70513}
}
Start for free →